<DOC>
	<DOCNO>NCT01660399</DOCNO>
	<brief_summary>This predictive , randomize , double-blind , multi-center trial go evaluate efficacy safety two regimen boanmycin plus docetaxel versus docetaxel alone second line treatment chemotherapy stage IIIb-IV postoperative recurrent squamous cell lung cancer patient .</brief_summary>
	<brief_title>Clinical Trial Boanmycin Hydrochloride With Docetaxel Patients With Lung Squamous Cell Cancer Chemotherapy</brief_title>
	<detailed_description>At present , reliable second line treatment except chemotherapy squamous cell carcinoma patient , current chemotherapy regimen , include docetaxel single agent know gold standard , weekly use docetaxel combination EGFR-TKI evidence high response rate prolong survival.On hand , adverse reaction chemotherapy make combine chemotherapy improve therapeutic effect . Boanmycin special pharmacological basis , well high purity , may obvious increase adverse reaction , probably improve effect chemotherapy . At time , low lung toxicity , especially combine use corticosteroid , background poor survival advance squamous cell lung cancer patient , chemotherapy regimen boanmycin plus docetaxel need investigate . This predictive , randomize , double-blind , multi-center trial go evaluate efficacy safety two regimen boanmycin plus docetaxel versus docetaxel alone second line treatment chemotherapy stage IIIb-IV postoperative recurrent squamous cell lung cancer patient . According test center , gender , disease staging ( stage IIIB , IV/recurrence ) pathologic type , patient squamous cell lung cancer stratify randomly assign one two group . In first group , 75 mg docetaxel per square meter body-surface area , administer day 1 , follow 5~6 mg boanmycin per square meter 5mg dexamethasone day 3,5,10 12 , cycle repeat every 21days . The second group receive reference treatment : docetaxel dose 75 mg per square meter administer day 1 three-week cycle . The efficacy evaluate use RESIST standard every 2 cycle treatment , regimen continue disease progression appearance tolerable toxicity .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<criteria>histologically cytology confirm III，IV operation recurrent squamous cell lung cancer ; disease progress firstline chemotherapy suitable EGFRTKI ; radiotherapy metastasis outside lung 4 week ; lesion measurable CT image measure follow criterion RECIST 1.1 2 week randomization ; ECOG scale 01 , expect survival &gt; 3 month ; white blood count ≥ 3,500/mm3 , absolute neutrophil≥ 1,500/mm3 , platelet count ≥ 100,000/mm3 , hemoglobin count≥ 90 g/dL；serum bilirubin level ≤ 1.5 upper limit normal ( ULN ) institution , aspartate aminotransferase , alanine aminotransferase alkaline phosphatase≤ 2.5 ULN , serum creatinine≤ 1.5 ULN ; good compliance； past history major operation 4 week ; involve clinical trial 4 week ; past history central nervous system relevant disease except wellcontrolled CNS metastasis ; past history cancer except cured nonmelanoma skin cancer cervical cancer ; concomitant treatment anticancer drug . pregnancy , breast feeding fertility take contraceptive device trial ; radiotherapy target lesion lung ; clear TKIrelated mutation EGFR ; severe heart disease , hypertension , diabetes mellitus active infection . past history allergy taxanes ; past history severe acute chronic kidney disease ; active hepatitis b HIV positive patient ; tolerate Corticosteroid ; past history COPD critical basic pulmonary disease ; history severe mental illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>salvage chemotherapy</keyword>
	<keyword>advanced squamous cell lung cancer</keyword>
	<keyword>Boanmycin</keyword>
</DOC>